SaponiQx and InvivoGen Launch STIMULON Cultured Plant Cell QS-21 Adjuvant for Commercial Purchase
August 12 2024 - 6:00AM
Business Wire
Agenus subsidiary, SaponiQx, a leader in saponin-based adjuvant
production and discovery, today announced the availability of
STIMULON™ cultured plant cell (cpc) QS-21 on InvivoGen’s
international retail infrastructure. SaponiQx’s STIMULON QS-21 is a
key adjuvant component in market-leading vaccines for shingles,
malaria, and respiratory syncytial virus. CpcQS-21 is derived from
a cultured plant cell source, offering a sustainable alternative to
conventional QS-21 extracted from a limited supply of tree bark.
This platform is designed to ensure a stable supply chain, uniform
quality, scalable manufacturing, and reduced cost.
Key Highlights:
- SaponiQx is enabling access to cpcQS-21 via InvivoGen,
who will market the product to labs, academic institutions, and
industry partners to study the applications and potential of this
adjuvant.
- Bolstering global supply chains by lessening the
reliance on bark extract as the sole source for QS-21. SaponiQx’s
scalable process now enables the pharma community to secure their
supply chains through diversity of supply, making pandemic quantity
vaccines more accessible.
- Innovating next generation adjuvant discovery by merging
synthetic biology with AI and Generative Molecular Design. SaponiQx
will discover and develop new saponin-based vaccine adjuvants to be
uniquely paired with antigens to elicit the desired immune response
for future health care solutions.
“We value our partnership with InvivoGen to bring cpcQS-21 to
the market,” said Rebecca Kurnat, Head of Operations at SaponiQx.
“SaponiQx's STIMULON cpcQS-21 offers a groundbreaking alternative
to tree bark derived product, ensuring consistent availability of
this critical vaccine adjuvant.”
cpcQS-21 is available now for purchase in 1, 5, and 25mg
aliquots at www.invivogen.com.
Forward Looking Statements
This press release includes forward-looking statements, subject
to risks and uncertainties, concerning the development of vaccines
and adjuvants. Refer to the Risk Factors in Agenus' latest
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the SEC for a detailed discussion of these risks.
About SaponiQx
Founded in 2021, SaponiQx, a subsidiary of Agenus Inc., stands
at the forefront of saponin-based adjuvant discovery and
manufacturing. Its mission is to provide scalable and affordable
vaccine adjuvants to enhance global health. Its proprietary
adjuvant, STIMULON QS-21, forms an integral part of the AS01
adjuvant used in several leading vaccines. STIMULON is a trademark
of Agenus Inc., the parent company of SaponiQx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240812667963/en/
SaponiQx communications@saponiqx.com